1. Article 82 and Predation: The (French) Glaxo Case
Konrad Stahl (Chair)
Philippe Choné (CC Position)
Michele Polo (Glaxo Position)
Eric Avenel (Academic Position)

2. Suggested points for discussion
What is the relevant market?
What is the relevant measure for a predatory price (given that the TP can be subject to manipulation)?
Can the exit of Flavelab be assigned to anticompetitive practice? How about the exit of Lilly?
If it was, how about the strength of the signal, given the market penetration of Panpharma?